1
|
Jiang W, Yang Q, Yang X, Gan R, Hua H, Ding Z, Si D, Zhu X, Wang X, Zhang H, Gao C. T cell proliferation-related subtypes, prognosis model and characterization of tumor microenvironment in head and neck squamous cell carcinoma. Heliyon 2024; 10:e34221. [PMID: 39082023 PMCID: PMC11284379 DOI: 10.1016/j.heliyon.2024.e34221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 07/04/2024] [Accepted: 07/05/2024] [Indexed: 08/02/2024] Open
Abstract
Background Thirty-three synthetic driver genes of T-cell proliferation have recently been identified through genome-scale screening. However, the tumor microenvironment (TME) cell infiltration, prognosis, and response to immunotherapy mediated by multiple T cell proliferation-related genes (TRGs) in patients with head and neck squamous cell carcinoma (HNSC) remain unclear. Methods This study examined the genetic and transcriptional changes in 771 patients with HNSC by analyzing the TRGs from two independent datasets. Two different subtypes were analyzed to investigate their relationship with immune infiltrating cells in the TME and patient prognosis. The study also developed and validated a risk score to predict overall survival (OS). Furthermore, to enhance the clinical utility of the risk score, an accurate nomogram was constructed by combining the characteristics of this study. Results The low-risk score observed in this study was associated with high levels of immune checkpoint expression and TME immune activation, indicating a favorable OS outcome. Additionally, various factors related to risk scores were depicted. Conclusion Through comprehensive analysis of TRGs in HNSC, our study has revealed the characteristics of the TME and prognosis, providing a basis for further investigation into TRGs and the development of more effective immunotherapy and targeted therapy strategies.
Collapse
Affiliation(s)
- Wanjin Jiang
- Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Wannan Medical College Yijishan Hospital, Wuhu, 241000, China
- Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China
| | - Qi Yang
- Department of Gastroenterology, The First Affiliated Hospital of Wannan Medical College Yijishan Hospital, Wuhu, 241000, China
| | - Xiaonan Yang
- Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China
| | - Ruijia Gan
- Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China
| | - Hongting Hua
- Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China
| | - Zhimin Ding
- Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China
| | - Dongyu Si
- Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China
| | - Xinbei Zhu
- Department of Otorhinolaryngology Head and Neck Surgery, The Second People’s Hospital of Hefei, Hefei, 230011, China
| | - Xu Wang
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China
| | - Huabing Zhang
- Department of Biochemistry & Molecular Biology, Metabolic Disease Research Center, School of Basic Medicine, Anhui Medical University, Hefei, 230032, China
| | - Chaobing Gao
- Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China
| |
Collapse
|
2
|
Liu J, Wang X, Jiang W, Azoitei A, Eiseler T, Eckstein M, Hartmann A, Stilgenbauer S, Elati M, Hohwieler M, Kleger A, John A, Wezel F, Zengerling F, Bolenz C, Günes C. Impairment of α-tubulin and F-actin interactions of GJB3 induces aneuploidy in urothelial cells and promotes bladder cancer cell invasion. Cell Mol Biol Lett 2024; 29:94. [PMID: 38956497 PMCID: PMC11218312 DOI: 10.1186/s11658-024-00609-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2024] [Accepted: 06/14/2024] [Indexed: 07/04/2024] Open
Abstract
BACKGROUND We have previously identified an unsuspected role for GJB3 showing that the deficiency of this connexin protein induces aneuploidy in human and murine cells and accelerates cell transformation as well as tumor formation in xenograft models. The molecular mechanisms by which loss of GJB3 leads to aneuploidy and cancer initiation and progression remain unsolved. METHODS GJB3 expression levels were determined by RT-qPCR and Western blot. The consequences of GJB3 knockdown on genome instability were assessed by metaphase chromosome counting, multinucleation of cells, by micronuclei formation and by the determination of spindle orientation. Interactions of GJB3 with α-tubulin and F-actin was analyzed by immunoprecipitation and immunocytochemistry. Consequences of GJB3 deficiency on microtubule and actin dynamics were measured by live cell imaging and fluorescence recovery after photobleaching experiments, respectively. Immunohistochemistry was used to determine GJB3 levels on human and murine bladder cancer tissue sections. Bladder cancer in mice was chemically induced by BBN-treatment. RESULTS We find that GJB3 is highly expressed in the ureter and bladder epithelium, but it is downregulated in invasive bladder cancer cell lines and during tumor progression in both human and mouse bladder cancer. Downregulation of GJB3 expression leads to aneuploidy and genomic instability in karyotypically stable urothelial cells and experimental modulation of GJB3 levels alters the migration and invasive capacity of bladder cancer cell lines. Importantly, GJB3 interacts both with α-tubulin and F-actin. The impairment of these interactions alters the dynamics of these cytoskeletal components and leads to defective spindle orientation. CONCLUSION We conclude that deregulated microtubule and actin dynamics have an impact on proper chromosome separation and tumor cell invasion and migration. Consequently, these observations indicate a possible role for GJB3 in the onset and spreading of bladder cancer and demonstrate a molecular link between enhanced aneuploidy and invasive capacity cancer cells during tumor cell dissemination.
Collapse
Affiliation(s)
- Junnan Liu
- Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany
- Department of Urology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA
| | - Xue Wang
- Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany
- Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN, USA
| | - Wencheng Jiang
- Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany
| | - Anca Azoitei
- Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany
| | - Tim Eiseler
- Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany
| | - Markus Eckstein
- Institute of Pathology, Friedrich-Alexander University, Erlangen, Germany
| | - Arndt Hartmann
- Institute of Pathology, Friedrich-Alexander University, Erlangen, Germany
| | | | - Mohamed Elati
- CANTHER, ONCOLille Institute, University of Lille, CNRS, UMR 1277, Inserm U9020, 59045, Lille Cedex, France
| | - Meike Hohwieler
- Institute of Molecular Oncology and Stem Cell Biology, Ulm University Hospital, Ulm, Germany
| | - Alexander Kleger
- Institute of Molecular Oncology and Stem Cell Biology, Ulm University Hospital, Ulm, Germany
| | - Axel John
- Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany
| | - Felix Wezel
- Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany
| | - Friedemann Zengerling
- Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany
| | - Christian Bolenz
- Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany
| | - Cagatay Günes
- Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
| |
Collapse
|
3
|
Deng D, Xu X, Cui T, Xu M, Luo K, Zhang H, Wang Q, Song C, Li C, Li G, Shang D. PBAC: A pathway-based attention convolution neural network for predicting clinical drug treatment responses. J Cell Mol Med 2024; 28:e18298. [PMID: 38683133 PMCID: PMC11057419 DOI: 10.1111/jcmm.18298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Revised: 03/05/2024] [Accepted: 03/25/2024] [Indexed: 05/01/2024] Open
Abstract
Precise and personalized drug application is crucial in the clinical treatment of complex diseases. Although neural networks offer a new approach to improving drug strategies, their internal structure is difficult to interpret. Here, we propose PBAC (Pathway-Based Attention Convolution neural network), which integrates a deep learning framework and attention mechanism to address the complex biological pathway information, thereby provide a biology function-based robust drug responsiveness prediction model. PBAC has four layers: gene-pathway layer, attention layer, convolution layer and fully connected layer. PBAC improves the performance of predicting drug responsiveness by focusing on important pathways, helping us understand the mechanism of drug action in diseases. We validated the PBAC model using data from four chemotherapy drugs (Bortezomib, Cisplatin, Docetaxel and Paclitaxel) and 11 immunotherapy datasets. In the majority of datasets, PBAC exhibits superior performance compared to traditional machine learning methods and other research approaches (area under curve = 0.81, the area under the precision-recall curve = 0.73). Using PBAC attention layer output, we identified some pathways as potential core cancer regulators, providing good interpretability for drug treatment prediction. In summary, we presented PBAC, a powerful tool to predict drug responsiveness based on the biology pathway information and explore the potential cancer-driving pathways.
Collapse
Affiliation(s)
- Dexun Deng
- The First Affiliated Hospital, Cardiovascular Lab of Big Data and Imaging Artificial Intelligence, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Hunan Provincial Key Laboratory of Multi‐omics And Artificial Intelligence of Cardiovascular DiseasesUniversity of South ChinaHengyangHunanChina
- School of ComputerUniversity of South ChinaHengyangHunanChina
| | - Xiaoqiang Xu
- The First Affiliated Hospital, Cardiovascular Lab of Big Data and Imaging Artificial Intelligence, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Hunan Provincial Key Laboratory of Multi‐omics And Artificial Intelligence of Cardiovascular DiseasesUniversity of South ChinaHengyangHunanChina
- The First Affiliated Hospital, Institute of Cardiovascular Disease, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Department of Cardiology, The First Affiliated Hospital, Hengyang Medical SchoolUniversity of South ChinaHengyangChina
| | - Ting Cui
- The First Affiliated Hospital, Cardiovascular Lab of Big Data and Imaging Artificial Intelligence, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Hunan Provincial Key Laboratory of Multi‐omics And Artificial Intelligence of Cardiovascular DiseasesUniversity of South ChinaHengyangHunanChina
| | - Mingcong Xu
- The First Affiliated Hospital, Cardiovascular Lab of Big Data and Imaging Artificial Intelligence, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Hunan Provincial Key Laboratory of Multi‐omics And Artificial Intelligence of Cardiovascular DiseasesUniversity of South ChinaHengyangHunanChina
| | - Kunpeng Luo
- Department of Gastroenterology and HepatologySecond Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiangChina
| | - Han Zhang
- The First Affiliated Hospital, Cardiovascular Lab of Big Data and Imaging Artificial Intelligence, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Hunan Provincial Key Laboratory of Multi‐omics And Artificial Intelligence of Cardiovascular DiseasesUniversity of South ChinaHengyangHunanChina
- School of ComputerUniversity of South ChinaHengyangHunanChina
| | - Qiuyu Wang
- The First Affiliated Hospital, Cardiovascular Lab of Big Data and Imaging Artificial Intelligence, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Hunan Provincial Key Laboratory of Multi‐omics And Artificial Intelligence of Cardiovascular DiseasesUniversity of South ChinaHengyangHunanChina
- School of ComputerUniversity of South ChinaHengyangHunanChina
- The First Affiliated Hospital, Institute of Cardiovascular Disease, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Department of Cardiology, The First Affiliated Hospital, Hengyang Medical SchoolUniversity of South ChinaHengyangChina
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Department of Cell Biology and Genetics, School of Basic Medical Sciences, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
| | - Chao Song
- The First Affiliated Hospital, Cardiovascular Lab of Big Data and Imaging Artificial Intelligence, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Hunan Provincial Key Laboratory of Multi‐omics And Artificial Intelligence of Cardiovascular DiseasesUniversity of South ChinaHengyangHunanChina
- School of ComputerUniversity of South ChinaHengyangHunanChina
- The First Affiliated Hospital, Institute of Cardiovascular Disease, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Department of Cardiology, The First Affiliated Hospital, Hengyang Medical SchoolUniversity of South ChinaHengyangChina
| | - Chao Li
- Department of AnesthesiologyThe First Affiliated Hospital of University of South ChinaHengyangPR China
| | - Guohua Li
- Department of Pathophysiology, Key Laboratory for Arteriosclerology of Hunan Province, MOE Key Lab of Rare Pediatric Diseases, Hengyang Medical SchoolInstitute of Cardiovascular Disease, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South ChinaHengyangHunanChina
| | - Desi Shang
- The First Affiliated Hospital, Cardiovascular Lab of Big Data and Imaging Artificial Intelligence, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Hunan Provincial Key Laboratory of Multi‐omics And Artificial Intelligence of Cardiovascular DiseasesUniversity of South ChinaHengyangHunanChina
- School of ComputerUniversity of South ChinaHengyangHunanChina
- The First Affiliated Hospital, Institute of Cardiovascular Disease, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Department of Cardiology, The First Affiliated Hospital, Hengyang Medical SchoolUniversity of South ChinaHengyangChina
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
- Department of Cell Biology and Genetics, School of Basic Medical Sciences, Hengyang Medical SchoolUniversity of South ChinaHengyangHunanChina
| |
Collapse
|
4
|
Tang L, Xu H, Wu T, Wu W, Lu Y, Gu J, Wang X, Zhou M, Chen Q, Sun X, Cai H. Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review. Discov Oncol 2024; 15:111. [PMID: 38602556 PMCID: PMC11009183 DOI: 10.1007/s12672-024-00902-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2023] [Accepted: 02/21/2024] [Indexed: 04/12/2024] Open
Abstract
Bladder cancer is one of the most frequent malignant tumors of the urinary system. The prevalence of bladder cancer among men and women is roughly 5:2, and both its incidence and death have been rising steadily over the past few years. At the moment, metastasis and recurrence of advanced bladder cancer-which are believed to be connected to the malfunction of multigene and multilevel cell signaling network-remain the leading causes of bladder cancer-related death. The therapeutic treatment of bladder cancer will be greatly aided by the elucidation of these mechanisms. New concepts for the treatment of bladder cancer have been made possible by the advancement of research technologies and a number of new treatment options, including immunotherapy and targeted therapy. In this paper, we will extensively review the development of the tumor microenvironment and the possible molecular mechanisms of bladder cancer.
Collapse
Affiliation(s)
- Liu Tang
- Department of Nursing, Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China
| | - Haifei Xu
- Department of Urology, Nantong Tumor Hospital and Tumor Hospital Affiliated to Nantong University, Nantong, China
| | - Tong Wu
- Department of Radiology, Nanjing Medical University The Fourth School of Clinical Medicine, Nanjing, Jiangsu, China
| | - Wenhao Wu
- Department of Radiology, Nanjing Medical University The Fourth School of Clinical Medicine, Nanjing, Jiangsu, China
| | - Yuhao Lu
- Department of Radiology, Nanjing Medical University The Fourth School of Clinical Medicine, Nanjing, Jiangsu, China
| | - Jijia Gu
- Department of Radiology, Nanjing Medical University The Fourth School of Clinical Medicine, Nanjing, Jiangsu, China
| | - Xiaoling Wang
- Department of Urology, Nantong Tumor Hospital and Tumor Hospital Affiliated to Nantong University, Nantong, China
| | - Mei Zhou
- Department of Nursing, Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
| | - Qiuyang Chen
- Department of Radiology, Nanjing Medical University The Fourth School of Clinical Medicine, Nanjing, Jiangsu, China.
| | - Xuan Sun
- Department of Radiology, Nanjing Medical University The Fourth School of Clinical Medicine, Nanjing, Jiangsu, China.
| | - Hongzhou Cai
- Department of Urology, Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
| |
Collapse
|
5
|
Sah DK, Arjunan A, Park SY, Lee B, Jung YD. Sulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells. Antioxidants (Basel) 2024; 13:406. [PMID: 38671854 PMCID: PMC11047376 DOI: 10.3390/antiox13040406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Revised: 03/22/2024] [Accepted: 03/25/2024] [Indexed: 04/28/2024] Open
Abstract
Colorectal cancer (CRC) stands as a major cause of cancer-related mortality globally, accounting for approximately 881,000 deaths each year. Traditional approaches such as chemotherapy and surgery have been the primary treatment modalities, yet the outcomes for patients with metastatic CRC are often unsatisfactory. Recent research has focused on targeting the pathways involved in oxidative stress, inflammation, and metastasis to enhance the survival of CRC patients. Within this context, sulforaphane (SFN), a notable phytochemical found predominantly in cruciferous vegetables, has been recognized as a potential anticancer agent. However, the specific mechanisms through which SFN may exert its chemopreventive effects in CRC remain unclear. This study explores the impact of SFN on IL-1β-induced IL-6 activation and MAPK and AP-1 signaling in HT-29 cells. Our findings reveal that SFN treatment not only diminishes IL-1β-stimulated IL-6 expression but also reduces oxidative stress by curtailing reactive oxygen species (ROS) production. Furthermore, it hinders the proliferation and invasiveness of HT-29 cells through the modulation of MAPK/AP-1 and STAT3 signaling pathways. These results indicate that SFN mitigates IL-1β-induced IL-6 expression in CRC cells by attenuating ROS production and disrupting MAPK/AP-1 signaling. This suggests that SFN holds significant potential as a chemotherapeutic agent for both treating and preventing CRC.
Collapse
Affiliation(s)
- Dhiraj Kumar Sah
- Department of Biochemistry, Chonnam National University Medical School, Hwasun 58128, Republic of Korea; (D.K.S.); (A.A.)
| | - Archana Arjunan
- Department of Biochemistry, Chonnam National University Medical School, Hwasun 58128, Republic of Korea; (D.K.S.); (A.A.)
| | - Seon Young Park
- Department of Internal Medicine, Chonnam National University Medical School, Gwangju 501190, Republic of Korea;
| | - Bora Lee
- Department of Biochemistry, Chonnam National University Medical School, Hwasun 58128, Republic of Korea; (D.K.S.); (A.A.)
| | - Young Do Jung
- Department of Biochemistry, Chonnam National University Medical School, Hwasun 58128, Republic of Korea; (D.K.S.); (A.A.)
| |
Collapse
|
6
|
Vukovic M, Chamlati JM, Hennenlotter J, Todenhöfer T, Lütfrenk T, Jersinovic S, Tsaur I, Stenzl A, Rausch S. Interleukin-1β/Interleukin (IL)-1-Receptor-Antagonist (IL1-RA) Axis in Invasive Bladder Cancer-An Exploratory Analysis of Clinical and Tumor Biological Significance. Int J Mol Sci 2024; 25:2447. [PMID: 38397123 PMCID: PMC10889501 DOI: 10.3390/ijms25042447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Revised: 02/06/2024] [Accepted: 02/13/2024] [Indexed: 02/25/2024] Open
Abstract
Previous data indicate a role of IL-1 and IL-1RA imbalance in bladder carcinoma (BC); the inhibition of IL-1 signaling might be considered a treatment option. Objective: To assess expression patterns and the prognostic role of IL-1β and IL-1RA in invasive BC and to evaluate their interaction with AKT signaling and proliferation. The study included two independent cohorts of n = 92 and n = 102 patients who underwent a radical cystectomy for BC. Specimen from BC and benign urothelium (n = 22 and n = 39) were processed to a tissue microarray and immunohistochemically stained for IL-1β, IL-1RA, AKT, and Ki-67. Expression scores were correlated to clinical variables and Ki-67 and AKT expression. An association with outcome was assessed using Wilcoxon Kruskal-Wallis tests, Chi-square tests or linear regression, dependent on the variable's category. Kaplan-Meier and Cox proportional hazard analyses were used to estimate recurrence-free (RFS), cancer-specific (CSS) and overall survival (OS). Both IL-1β and IL-1RA were significantly overexpressed in invasive BC compared to benign urothelium in both cohorts (p < 0.005). IL-1β was associated with vascular invasion (210 vs. 183, p < 0.02), lymphatic invasion (210 vs. 180, <0.05) and G3 cancer (192 vs. 188, <0.04). The survival analysis revealed favorable RFS, CSS, and OS in the case of high IL-1β expression (p < 0.02, <0.03, and <0.006, respectively). Multivariate analyses revealed an independent impact of (low) IL1β expression on RFS, CSS, and OS. The IL-1β and IL-1β/IL-1RA ratios were positively correlated to the AKT expression (p < 0.05 and <0.01, respectively). Additionally, the high expression of Ki-67 (>15%) correlated with higher levels of IL-1β (p = 0.01). The overexpression of IL-1β and IL-1RA is frequently found in BC, with a prognostic significance observed for the IL-1β protein expression. The observed link between the IL-1β/IL-1RA axis and AKT signaling may indicate possible autophagy activation processes besides the known tumor-promoting effects of AKT.
Collapse
Affiliation(s)
- Marko Vukovic
- Department of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany (S.J.)
- Department of Urology, Clinical Center of Montenegro, University of Montenegro, 81000 Podgorica, Montenegro
| | - Jorge M. Chamlati
- Department of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany (S.J.)
| | - Jörg Hennenlotter
- Department of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany (S.J.)
| | - Tilman Todenhöfer
- Department of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany (S.J.)
| | - Thomas Lütfrenk
- Department of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany (S.J.)
| | - Sebastian Jersinovic
- Department of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany (S.J.)
| | - Igor Tsaur
- Department of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany (S.J.)
| | - Arnulf Stenzl
- Department of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany (S.J.)
| | - Steffen Rausch
- Department of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany (S.J.)
| |
Collapse
|
7
|
Rapulana AM, Mpotje T, Baiyegunhi OO, Ndlovu H, Smit TK, McHugh TD, Marakalala MJ. Combined analysis of host IFN-γ, IL-2 and IP-10 as potential LTBI biomarkers in ESAT-6/CFP-10 stimulated blood. FRONTIERS IN MOLECULAR MEDICINE 2024; 4:1345510. [PMID: 39086434 PMCID: PMC11285608 DOI: 10.3389/fmmed.2024.1345510] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Accepted: 01/12/2024] [Indexed: 08/02/2024]
Abstract
Background: Accurate diagnosis of latent tuberculosis infected (LTBI) individuals is important in identifying individuals at risk of developing active tuberculosis. Current diagnosis of LTBI routinely relies on the detection and measurement of immune responses using the Tuberculin Skin Test (TST) and interferon gamma release assays (IGRAs). However, IGRA, which detects Mycobacterium tuberculosis specific IFN-γ, is associated with frequent indeterminate results, particularly in immunosuppressed patients. There is a need to identify more sensitive LTBI point of care diagnostic biomarkers. The aim of this study was to assess the validity of early secreted antigen target 6 kDa (ESAT-6) and culture filtrate protein 10 (CFP-10) stimulated plasma to identify additional cytokines and chemokines as potential biomarkers of LTBI. Method: The levels of 27 cytokines and chemokines were measured by Bio-Plex Pro cytokine, chemokine and growth factor assay in ESAT-6 and CFP-10 co-stimulated plasma from 20 LTBI participants with positive IGRA (Quantiferon TB Gold plus) and 20 healthy controls with negative IGRA. Traditional ELISA was used to validate the abundance of the best performing markers in 70 LTBI and 72 healthy participants. All participants were HIV negative. Results: We found that Interleukin 1 receptor antagonist (IL1ra) (p = 0.0056), Interleukin 2 (IL-2) (p < 0.0001), Interleukin 13 (IL-13) (p < 0.0001), Interferon gamma-induced protein 10 (IP-10) (p < 0.0001), and Macrophage inflammatory protein-1 beta (MIP1b) (p = 0.0010) were significantly higher in stimulated plasma of LTBI compared to healthy individuals. Stimulated plasma IL-2 (cutoff 100 pg/mL), IP-10 (cutoff 300 pg/mL) and IL-13 (5 pg/mL) showed potential in diagnosing LTBI with PPV = 100%, 0.89.4%, and 80.9% and NPV = 86.9%, 0.85.7%, and 84.2%, respectively. Conclusion: Our data shows that co-stimulating whole blood with ESAT-6 and CFP-10 may help distinguish LTBI from healthy individuals. We also identified IL-2 and IP-10 as potential biomarkers that could be added to the currently used IFN-γ release assays in detection of LTBI.
Collapse
Affiliation(s)
- Antony M. Rapulana
- School of Laboratory Medicine and Medical Science, University of Kwazulu-Natal, Durban, Kwazulu-Natal, South Africa
- Africa Health Research Institute, Durban, Kwazulu-Natal, South Africa
- Division of Infection and Immunity, UCL Centre for Clinical for Clinical Microbiology, University College London, London, United Kingdom
| | - Thabo Mpotje
- School of Laboratory Medicine and Medical Science, University of Kwazulu-Natal, Durban, Kwazulu-Natal, South Africa
- Africa Health Research Institute, Durban, Kwazulu-Natal, South Africa
| | | | - Hlumani Ndlovu
- Division of Chemical and System Biology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - Theresa K. Smit
- School of Laboratory Medicine and Medical Science, University of Kwazulu-Natal, Durban, Kwazulu-Natal, South Africa
- Africa Health Research Institute, Durban, Kwazulu-Natal, South Africa
| | - Timothy D. McHugh
- Division of Infection and Immunity, UCL Centre for Clinical for Clinical Microbiology, University College London, London, United Kingdom
| | - Mohlopheni J. Marakalala
- School of Laboratory Medicine and Medical Science, University of Kwazulu-Natal, Durban, Kwazulu-Natal, South Africa
- Africa Health Research Institute, Durban, Kwazulu-Natal, South Africa
- Division of Infection and Immunity, UCL Centre for Clinical for Clinical Microbiology, University College London, London, United Kingdom
| |
Collapse
|
8
|
Shen B, Zhang G, Liu Y, Wang J, Jiang J. Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma. Genes (Basel) 2022; 13:genes13101834. [PMID: 36292719 PMCID: PMC9601963 DOI: 10.3390/genes13101834] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2022] [Revised: 10/06/2022] [Accepted: 10/08/2022] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND Hepatocellular carcinoma (HCC) originates from the hepatocytes and accounts for 90% of liver cancer. The study intends to identify novel prognostic biomarkers for predicting the prognosis of HCC patients based on TCGA and GSE14520 cohorts. METHODS Differential analysis was employed to obtain the DEGs (Differentially Expressed Genes) of the TCGA-LIHC-TPM cohort. The lasso regression analysis was applied to build the prognosis model through using the TCGA cohort as the training group and the GSE14520 cohort as the testing group. Next, based on the prognosis model, we performed the following analyses: the survival analysis, the independent prognosis analysis, the clinical feature analysis, the mutation analysis, the immune cell infiltration analysis, the tumor microenvironment analysis, and the drug sensitivity analysis. Finally, the survival time of HCC patients was predicted by constructing nomograms. RESULTS Through the lasso regression analysis, we obtained a prognosis model of ten genes including BIRC5 (baculoviral IAP repeat containing 5), CDK4 (cyclin-dependent kinase 4), DCK (deoxycytidine kinase), HSPA4 (heat shock protein family A member 4), HSP90AA1 (heat shock protein 90 α family class A member 1), PSMD2 (Proteasome 26S Subunit Ubiquitin Receptor, Non-ATPase 2), IL1RN (interleukin 1 receptor antagonist), PGF (placental growth factor), SPP1 (secreted phosphoprotein 1), and STC2 (stanniocalcin 2). First, we found that the risk score is an independent prognosis factor and is related to the clinical features of HCC patients, covering AFP (α-fetoprotein) and stage. Second, we observed that the p53 mutation was the most obvious mutation between the high-risk and low-risk groups. Third, we also discovered that the risk score is related to some immune cells, covering B cells, T cells, dendritic, macrophages, neutrophils, etc. Fourth, the high-risk group possesses a lower TIDE score, a higher expression of immune checkpoints, and higher ESTIMATE score. Finally, nomograms include the clinical features and risk signatures, displaying the clinical utility of the signature in the survival prediction of HCC patients. CONCLUSIONS Through the comprehensive analysis, we constructed an immune-related prognosis model to predict the survival of HCC patients. In addition to predicting the survival time of HCC patients, this model significantly correlates with the tumor microenvironment. Furthermore, we concluded that these ten immune-related genes (BIRC5, CDK4, DCK, HSPA4, HSP90AA1, PSMD2, IL1RN, PGF, SPP1, and STC2) serve as novel targets for antitumor immunity. Therefore, this study plays a significant role in exploring the clinical application of immune-related genes.
Collapse
|
9
|
DI MAIDA F, GROSSO AA, TELLINI R, LAMBERTINI L, LO RE M, CADENAR A, GIUDICI S, GIORGIONE R, ROSSI V, ANTONUZZO L, MINERVINI A, MARI A. Analysis of molecular and clinical markers of resistance to bacillus of Calmette-Guérin immunotherapy in patients with urothelial non-muscle invasive bladder cancer. Minerva Urol Nephrol 2022; 74:642-646. [DOI: 10.23736/s2724-6051.22.04959-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
10
|
Melzer MK, Breunig M, Arnold F, Wezel F, Azoitei A, Roger E, Krüger J, Merkle J, Schütte L, Resheq Y, Hänle M, Zehe V, Zengerling F, Azoitei N, Klein L, Penz F, Singh SK, Seufferlein T, Hohwieler M, Bolenz C, Günes C, Gout J, Kleger A. Organoids at the PUB: The Porcine Urinary Bladder Serves as a Pancreatic Niche for Advanced Cancer Modeling. Adv Healthc Mater 2022; 11:e2102345. [PMID: 35114730 DOI: 10.1002/adhm.202102345] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 12/17/2021] [Indexed: 12/17/2022]
Abstract
Despite intensive research and progress in personalized medicine, pancreatic ductal adenocarcinoma remains one of the deadliest cancer entities. Pancreatic duct-like organoids (PDLOs) derived from human pluripotent stem cells (PSCs) or pancreatic cancer patient-derived organoids (PDOs) provide unique tools to study early and late stage dysplasia and to foster personalized medicine. However, such advanced systems are neither rapidly nor easily accessible and require an in vivo niche to study tumor formation and interaction with the stroma. Here, the establishment of the porcine urinary bladder (PUB) is revealed as an advanced organ culture model for shaping an ex vivo pancreatic niche. This model allows pancreatic progenitor cells to enter the ductal and endocrine lineages, while PDLOs further mature into duct-like tissue. Accordingly, the PUB offers an ex vivo platform for earliest pancreatic dysplasia and cancer if PDLOs feature KRASG12D mutations. Finally, it is demonstrated that PDOs-on-PUB i) resemble primary pancreatic cancer, ii) preserve cancer subtypes, iii) enable the study of niche epithelial crosstalk by spiking in pancreatic stellate and immune cells into the grafts, and finally iv) allow drug testing. In summary, the PUB advances the existing pancreatic cancer models by adding feasibility, complexity, and customization at low cost and high flexibility.
Collapse
Affiliation(s)
- Michael Karl Melzer
- Department of Urology, Ulm University, Ulm, 89081, Germany
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
| | - Markus Breunig
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
| | - Frank Arnold
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
| | - Felix Wezel
- Department of Urology, Ulm University, Ulm, 89081, Germany
| | - Anca Azoitei
- Department of Urology, Ulm University, Ulm, 89081, Germany
| | - Elodie Roger
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
| | - Jana Krüger
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
| | - Jessica Merkle
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
- Core Facility Organoids, Ulm University, Ulm, 89081, Germany
| | - Lena Schütte
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
| | - Yazid Resheq
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
| | - Mark Hänle
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
| | - Viktor Zehe
- Department of Urology, Ulm University, Ulm, 89081, Germany
| | | | - Ninel Azoitei
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
| | - Lukas Klein
- Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medicine Goettingen, Goettingen, 37075, Germany
| | - Frederike Penz
- Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medicine Goettingen, Goettingen, 37075, Germany
| | - Shiv K Singh
- Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medicine Goettingen, Goettingen, 37075, Germany
| | | | - Meike Hohwieler
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
| | | | - Cagatay Günes
- Department of Urology, Ulm University, Ulm, 89081, Germany
| | - Johann Gout
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
| | - Alexander Kleger
- Department of Internal Medicine I, Ulm University, Ulm, 89081, Germany
- Core Facility Organoids, Ulm University, Ulm, 89081, Germany
| |
Collapse
|